Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator

Executive Summary

The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.


Related Content

TMS Stroke Deal Suggests No Big Buy From Biogen Yet
Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis
Biogen, AbbVie Withdraw Struggling MS Drug Zinbryta Due To Safety Issues
Biogen Spooks With Phase III Aducanumab Changes
A Deal For Biogen, But Not The One Investors Are Waiting For
Pfizer Exits Early Neuroscience, But M&A Could Allow Later Re-Entry


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts